MRK vs. TEVA: Merck vs. Teva Pharmaceutical Stock Comparison
How do Merck (MRK) and Teva Pharmaceutical (TEVA) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Merck (MRK) and Teva Pharmaceutical (TEVA) are both classified in the Pharmaceuticals sub-industry within the broader Pharmaceuticals industry, placing them in the closest GICS peer bucket.
Merck (MRK) trades as ordinary local shares, while Teva Pharmaceutical (TEVA) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | MRK | TEVA |
|---|---|---|
| Name | Merck & Co., Inc. | Teva Pharmaceutical Industries Ltd. ADR |
| Country/Region | United States | Israel |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Pharmaceuticals | Pharmaceuticals |
| GICS Sub-Industry | Pharmaceuticals | Pharmaceuticals |
| Market Capitalization | 361.73 billion USD | 49.72 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | NYSE |
| Listing Date | January 2, 1962 | February 16, 1982 |
| Security Type | Common Stock | ADR |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | MRK | TEVA |
|---|---|---|
| Total Return (1Y) | 76.14% | 79.58% |
| Total Return (3Y, Annualized) | 16.48% | 69.94% |
| Total Return (5Y, Annualized) | 15.77% | 35.86% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | MRK | TEVA |
|---|---|---|
| Volatility (1Y, Annualized) | 30.24% | 33.95% |
| Beta (5Y) | 0.11 | 0.96 |
| Max Drawdown (5Y) | -43.44% | -43.70% |
| Avg. Volume (3M) | 10.24M | 5.91M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | MRK | TEVA |
|---|---|---|
| Sharpe Ratio (1Y) | 2.38 | 2.22 |
| Sortino Ratio (1Y) | 4.33 | 3.94 |
Profitability
ROE (TTM)
Teva Pharmaceutical (TEVA) at 6.65% sits in the top ROE quartile, while Merck (MRK) at 5.06% is closer to the peer norm — stronger capital efficiency for TEVA.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.06%
- Max
- 109.18%
- Q3
- 6.23%
- MRK
- 5.06%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.65%
- Max
- 109.18%
- TEVA
- 6.65%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Both Merck (MRK) at 3.64% and Teva Pharmaceutical (TEVA) at 2.94% keep about the typical share of revenue as profit for their industries — neither bottom line stands out from peers.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
3.64%
- Max
- 18.05%
- Q3
- 4.78%
- MRK
- 3.64%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.94%
- Max
- 18.05%
- Q3
- 4.78%
- TEVA
- 2.94%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Both Merck (MRK) at 35.22% and Teva Pharmaceutical (TEVA) at 27.40% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
35.22%
- Max
- 83.12%
- MRK
- 35.22%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
27.40%
- Max
- 83.12%
- TEVA
- 27.40%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | MRK | TEVA |
|---|---|---|
| ROE (TTM) | 5.06% | 6.65% |
| ROA (TTM) | 11.29% | 5.35% |
| Net Margin (TTM) | 3.64% | 2.94% |
| Operating Margin (TTM) | 35.22% | 27.40% |
| Gross Margin (TTM) | 75.20% | 53.51% |
Growth
Revenue Growth
Both Merck (MRK) at 1.31% and Teva Pharmaceutical (TEVA) at 4.31% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Only one side can be read here: Merck (MRK) reports EPS growth of 8.01%, ranked against its industry; Teva Pharmaceutical (TEVA) has no EPS growth figure this period.
Growth Metrics
| Metric | MRK | TEVA |
|---|---|---|
| Revenue Growth (YoY) | 1.31% | 4.31% |
| Revenue Growth (3Y CAGR) | 3.12% | 4.96% |
| EPS Growth (YoY) | 8.01% | -- |
| EPS Growth (3Y CAGR) | 8.43% | -- |
Financial Strength
Current Ratio (MRQ)
Both Merck (MRK) at 1.35 and Teva Pharmaceutical (TEVA) at 0.95 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.35
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- MRK
- 1.35
- Min
- 0.10
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.95
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- TEVA
- 0.95
- Min
- 0.10
Debt / Equity (MRQ)
Both balance sheets lean debt-heavy versus peers, but TEVA is more stretched: Merck (MRK) at 1.20 sits in the higher-leverage quartile and Teva Pharmaceutical (TEVA) at 2.13 is above its industry benchmark range.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.20
- Max
- 1.42
- MRK
- 1.20
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.13
- TEVA
- 2.13
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | MRK | TEVA |
|---|---|---|
| Current Ratio (MRQ) | 1.35 | 0.95 |
| Debt / Equity (MRQ) | 1.20 | 2.13 |
| Net Debt / EBITDA | 1.50 | 2.93 |
Dividends
Dividend Yield (TTM)
Teva Pharmaceutical (TEVA) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Merck (MRK) reports a yield of 2.29%, ranking against industry peers normally.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.29%
- MRK
- 2.29%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Merck (MRK) reports payout ratio above 100% at 343.43%, meaning dividends exceeded current-period earnings; Teva Pharmaceutical (TEVA) pays no dividend (payout 0.00%).
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
343.43%
- MRK
- 343.43%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- TEVA
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | MRK | TEVA |
|---|---|---|
| Dividend Yield (TTM) | 2.29% | 0.00% |
| Dividend Payout Ratio (TTM) | 343.43% | 0.00% |
Valuation
P/E Ratio (TTM)
Both Merck (MRK) at 148.21 and Teva Pharmaceutical (TEVA) at 99.09 trade above their industries’ P/E ratio peer ranges, pointing to unusually expensive trailing earnings relative to peers.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
148.21
- MRK
- 148.21
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
99.09
- TEVA
- 99.09
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Teva Pharmaceutical (TEVA) at 2.89 sits in the cheaper P/S ratio quartile while Merck (MRK) at 5.37 prices around its industry’s middle — TEVA costs less per dollar of sales, though read it alongside growth and margins.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.37
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- MRK
- 5.37
- Q1
- 3.01
- Min
- 0.01
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.89
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- TEVA
- 2.89
- Min
- 0.01
P/B Ratio (MRQ)
Teva Pharmaceutical (TEVA) at 6.23 is valued about in line with its industry on P/B ratio, while Merck (MRK) at 8.06 carries an above-peer premium to book — MRK is pricier on assets.
MRK
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.06
- Max
- 13.53
- MRK
- 8.06
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
TEVA
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.23
- Max
- 13.53
- Q3
- 6.54
- TEVA
- 6.23
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | MRK | TEVA |
|---|---|---|
| P/E Ratio (TTM) | 148.21 | 99.09 |
| P/S Ratio (TTM) | 5.37 | 2.89 |
| P/B Ratio (MRQ) | 8.06 | 6.23 |
| Free Cash Flow Yield (TTM) | 3.88% | 3.00% |